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FPIN's Clinical Inquiries 
Glucosamine and Chondroitin for Osteoarthritis 
Clinical Question 
Does glucosamine or chondroitin reduce pain, improve functional status, or improve prognosis in 
patients with osteoarthritis? 
Evidence-Based Answer 
Glucosamine reduces pain and improves function in patients with knee or hip osteoarthritis. 
(Strength of recommendation: B, based on systematic reviews and a meta-analysis) 
Glucosamine may be beneficial in other forms of osteoarthritis as well. (Strength of 
recommendation: B, based on a randomized controlled trial [RCT]) 
Chondroitin has not consistently been found to improve pain or functional status. (Strength of 
recommendation: B, based on a systematic review and a meta-analysis) 
Combination glucosamine and chondroitin therapy with camphor improved pain when applied 
topically. Combination therapy with methylsulfonylmethane given orally results in improved 
pain relief, function, and swelling. (Strength of recommendation: B, based on RCTs) 
Glucosamine may slow the progression of joint space narrowing, but there is no evidence that 
directly relates it to symptoms or prognosis of knee osteoarthritis. (Strength of recommendation: 
B, based on a meta-analysis and an RCT) 
Evidence Summary 
Reports from European trials suggest that glucosamine relieves the pain of osteoarthritis, 
although some of the earlier RCTs were of marginal quality and potentially biased because of 
manufacturer sponsorship.1 Chondroitin has been investigated less often and in a greater variety 
of dosages. One systematic review1 suggested that glucosamine and chondroitin improved pain 
relief and function; however, poor-quality trials and publication bias made the data difficult to 
interpret. Another systematic review2 found that glucosamine significantly reduced pain 
compared with placebo and nonsteroidal anti-inflammatory drugs (NSAIDs). A subsequent 
meta-analysis3 compared either glucosamine or chondroitin with placebo in persons with hip and 
knee osteoarthritis and found that five persons with osteoarthritis had to be treated with 
glucosamine or chondroitin for one to benefit. 
Three small RCTs found no improvement in pain relief or function with glucosamine treatment 
of knee osteoarthritis for less than six months; however, another study found improvement in 
functional pain of temporomandibular joint osteoarthritis treated for this same period.4 Two 
trials compared glucosamine with placebo over three years and demonstrated improvement in 
pain and function.4 
One recent RCT5 evaluated glucosamine given for 12 weeks to persons with knee osteoarthritis. 
Two different glucosamine preparations were utilized during the trial because the manufacturer 
withdrew the original supply. There was no significant difference between the glucosamine and 
placebo groups regarding the mean changes in pain, stiffness, or function. There was a decrease 
in pain scores seen during the RCT, but it was not statistically significant. A larger mean change 
in pain scores was seen in those receiving glucosamine hydrochloride than in those receiving 
glucosamine sulfate; however, this was not statistically significant. Another RCT6 evaluated 
flares of osteoarthritis and pain, stiffness, and function in patients receiving glucosamine 
compared with those receiving placebo over a six-month period. There was similar disease flare 
in patients receiving glucosamine and placebo, and no differences in pain and function. 
No RCTs evaluated glucosamine in combination with chondroitin; however, two RCTs 
compared glucosamine, chondroitin, and manganese with placebo with conflicting results.4 
Persons with knee osteoarthritis showed a greater reduction in pain at eight weeks using a topical 
preparation of glucosamine, chondroitin, and camphor compared with placebo but with no 
statistically significant change in function or stiffness.7 
Another study8 evaluated glucosamine, methylsulfonylmethane (a form of dimethyl sulfoxide), a 
combination of the two, and placebo in patients with mild to moderate osteoarthritis. The 
glucosamine, methylsulfonylmethane, and combination groups experienced a reduction in pain 
and swelling, with combination therapy resulting in a more rapid and significant improvement in 
symptoms than either compound alone.8 
Three RCTs used joint space narrowing to measure disease progression of knee osteoarthritis.4 
Methodologic difficulties in standardization of joint space width measurements and knee 
radiographs limited definite conclusions on the effectiveness of glucosamine as a disease-
modifying agent; however, in two RCTs,3 patients receiving glucosamine in a dosage of 1,500 
mg per day for three years demonstrated 0.27 mm less joint space narrowing than those taking 
placebo (95% confidence interval, 0.13 to 0.41 mm). Another study9 demonstrated that in mild 
and severe knee osteoarthritis, approximately five patients needed to be treated with glucosamine 
to prevent one patient from experiencing joint space narrowing of at least 0.5 mm over three 
years. 
Recommendations from Others 
The American Pain Society recommends that adults with osteoarthritis be encouraged to take 
1,500 mg of glucosamine daily as a dietary supplement but does not specifically recommend it as 
pharmacologic management for pain.10 
The American College of Rheumatology Subcommittee on Osteoarthritis currently has no 
recommendations regarding the use of glucosamine or chondroitin in the treatment of knee 
osteoarthritis11; however, during their 2005 annual meeting, preliminary results from the 
Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) were revealed. It was indicated in 
the presentation that glucosamine and chondroitin in combination may be effective in treating 
knee osteoarthritis, but final recommendations await the publication of results.12 
Clinical Commentary 
Sufficient evidence exists from studies of persons with hip or knee osteoarthritis to support the 
use of glucosamine as a safe and effective alternative treatment. With the potential harmful 
effects of chronic NSAID and acetaminophen use and a reluctance to begin chronic narcotic 
therapy for mild osteoarthritis, glucosamine and possibly chondroitin offer viable, low-cost 
treatment options or adjuvant medications. Patients should be advised to take 1,500 mg of 
glucosamine daily, either once daily or in divided doses three times daily, and to continue 
therapy for at least four to eight weeks to allow for onset of benefit. It remains to be seen 
whether one preparation of glucosamine is more effective than another and whether dosing 
should be in a single daily dose or divided. 
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